The clinical success of CAR T-cell therapy has sparked increased interest and investments in cell therapy applications. A key component of any therapeutic developer’s risk mitigation strategy is ensuring that the manufacturing workflow incorporates equipment and reagents suitable for clinical manufacturing.
Thermo Fisher Scientific is focused on providing manufacturing solutions that are appropriate for the long-term commercialization of therapeutic products through the addition of new innovative technologies to the Gibco Cell Therapy Systems (CTS) product suite.
This application note from Thermo Fisher Scientific discusses the application of the CTS Xenon Electroporation System and CTS TrueCut Cas9 Protein for efficient gene modification in cell therapy applications, highlighting their potential in clinical cell therapy manufacturing and their performance in terms of viability, cell expansion, and transfection efficiency.
Offered Free by: Thermo Fisher Scientific
See All Resources from: Thermo Fisher Scientific